PRAX Takes on U.S. Mental Health Crisis

<p>President and CEO of Praxis Precision Medicines (PRAX) Marcio Souza joins The Watch List one year following the company's public listing. Souza talks about how the biopharmaceutical company is attempting to combat the mental health crisis overtaking the U.S. Praxis develops therapies for central nervous system disorders characterized by neuronal imbalance like major depressive disorder and posttraumatic stress disorder. </p>